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Background: Inconclusive results of serological diagnosis in Chagas disease have an important impact on blood
banks worldwide, reflecting in the high number of discarded bags or in an increased transmission by blood
transfusion. Molecular techniques such as qPCR have been used for diagnosis and to monitor Trypanosoma cruzi
load in peripheral blood samples. A promising perspective refers to the possibility of parasite DNA detection in
serum, taking advantage in using the same samples collected for serological screening.
Methods: In order to evaluate the effectiveness of a qPCR strategy for detecting and quantifying T. cruzi DNA in
serum, we selected 40 chronic Chagas disease patients presenting different clinical manifestations: Cardiac (23),
Digestive (4), Mixed form [cardiodigestive] (7), and asymptomatic (6). Twenty seronegative individuals from
non-endemic areas were included as controls. Samples were extracted using QIAamp DNA mini kit (QIAGEN)
and qPCR was performed in a multiplex format with TaqMan probes for the nuclear satellite DNA of T. cruzi and
for the human RNase P gene. In addition, DNA migration to serum during blood coagulation was assessed using
a commercial exogenous control (Exo IPC, Applied Biosystems) in a separate qPCR reaction.
Results: The comparative duplex qPCR analysis revealed that, even with an increase in Ct values, it was
possible to detect all DNA targets in serum. In addition, the same linearity range for T. cruzi quantification (from
105 to 0.5 par. eq./mL) between serum, blood or culture samples (T. cruzi epimastigotes – Cl Brener strain) was
found. When patient samples were evaluated, no significant differences in parasite load between the distinct
clinical manifestations were found for both blood and serum samples. Moreover, median values of parasite
burden were 1.125 and 1.230 par. eq./mL for serum and blood, respectively. Using serology as gold standard,
we found 95% sensitivity for T. cruzi detection in serum and 97.5% for blood, and 100% specificity for both
samples.
Conclusions: Taken together, our data indicate the potential of using serum samples for molecular diagnosis
and parasite load quantification by qPCR, suggesting its use in reference laboratories for the diagnosis of
Chagas disease patients.
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Chagas disease is caused by the protozoan Trypanosoma
cruzi and represents the third-highest parasitic disease bur-
den after malaria and schistosomiasis [1,2]. It remains a
relevant and endemic public health issue in 21 endemic
countries of America, with an estimated 8 million people
already infected and about 50,000 new cases per year [3,4].
In addition, cases of Chagas disease due to blood transfu-
sion and organ transplantation have been increasingly
detected in the United States, Canada, many European
countries and Oceania, as consequence of intense migra-
tion of Latin America infected individuals to non-endemic
countries [5,6]. In this context, there is an urgent need for
improving the surveillance on neglected tropical diseases
for reducing the elevated number of undiagnosed Chagas
disease cases in these countries [7,8].
The current diagnostic methods for Chagas disease are
not satisfactory [3], being performed through the detection
of parasites (or parts of its content) in blood or the pres-
ence of parasite-specific antibodies in patient’s serum [9].
The results obtained by serological tests are often inconclu-
sive and available kits are expensive and present rather low
reproducibility, due to the use of non-defined reagents. In
general, serological doubtful results can bring a significant
impact in blood bank screening leading to an increment of
discarded blood bags. In Brazil, it is estimated 55,000 sero-
positive donors [10,11] and the risk of transfusion transmis-
sion via contaminated blood is about 12% - 25% [12]. In the
last decade, concerning the blood banks of Pernambuco
state, the proportion of inconclusive serology by two or
more tests (indirect haemagglutination, indirect immuno-
fluorescence and enzyme-linked immunosorbent assays)
was higher than the concordance of positive results ob-
tained by these tests [13]. In this sense, more reliable diag-
nostic methods for Chagas disease as well as biomarkers
for assessment treatment response are urgently needed
[9,14]. Quantitative PCR (qPCR) based assays could fill
these gaps providing higher sensitivity and specificity than
conventional methods to detect and quantify T. cruzi DNA
in Chagas disease patients [15-18].
Herein, we evaluated the effectiveness of a duplex
qPCR strategy based on TaqMan probes for detection
and quantification of T. cruzi load in serum samples
from chronic Chagas disease patients. Comparing the
results obtained with peripheral blood samples, the data
indicated the potential of using serum samples for mo-
lecular diagnosis and parasite load quantification, thus
suggesting the use of qPCR in reference laboratories for
the diagnosis of Chagas disease patients.
Methods
Ethics, consent and permissions
Forty seropositive Chagas disease chronic patients (aged
18 to 73 with a median of 62 years; 22 females and 18males) assisted at the Ambulatório de doença de Chagas e
Insuficiência Cardíaca do Pronto Socorro Cardiológico de
Pernambuco (PROCAPE) – Universidade de Pernambuco
(UPE), Brazil participated in the study. The serodiagnosis
to confirm the infection was performed by both, conven-
tional and recombinant enzyme-linked immunosorbent
assays–CHAGAS TEST ELISA III (ABBOT/BiosChile -
Bioschile Ingenieria Genética S.A., Santiago, Chile) and
Imuno-Elisa CHAGAS (WAMA Diagnóstica, São Carlos,
São Paulo, Brasil), following the recommendation of the
Ministry of Health of Brazil (Technical Note 03/06-
CGLAB/CGDT/DEVEP/SVS/MS) [9,19]. Patients were
classified accordingly to their clinical manifestations as
follows: cardiac (twenty three); digestive (four); cardiodi-
gestive (seven); asymptomatic (six) [9]. Additionally, 20 in-
dividuals without T. cruzi infection (negative serology)
living in non-endemic Chagas disease areas were included
as control group. The individuals recruited for this study
did not receive any blood transfusion or organ transplant-
ation prior to blood harvesting. The study was approved
by the ethical committee of the Centro de Pesquisas
Aggeu Magalhães from Fiocruz (CAEE: 0096.0.095.000-
07), following the principles expressed in the Declaration
of Helsinki. Chagas disease patients and healthy individ-
uals participated as volunteers and agreed to the “Terms
of Free and Informed Consent”; written informed con-
sents were obtained.
DNA extraction from human blood and serum
For each individual, ten milliliters of venous blood were
collected. Five milliliters were immediately transferred to
a BD Vacutainer® Plus Plastic Serum tube and remained
resting for 30 min at room temperature, in order to gen-
erate the clot from blood cells and the serum phase. The
five mL remaining blood were transferred to a BD Vacu-
tainer® Plus Plastic EDTA K3 tube. DNA extraction was
performed from 200 μL of serum and blood samples, as
described by Moreira et al. [20] using the QIAamp DNA
Mini kit (Qiagen, Valencia, CA). The DNA eluate was
stored at - 20°C until use in qPCR analysis.
Quantitative duplex Real-Time PCR (qPCR)
The qPCR reactions were carried out with 5 μL DNA; 2X
TaqMan® Universal PCR Master Mix AmpErase® from Ap-
plied Biosystems; 300nM cruzi1 (5′ASTCGGCTGATCG
TTTTCGA3′) and cruzi2 (5′AATTCCTCCAAGCAGCG-
GATA3′) primers and 100nM cruzi3 probe (5′FAM-CA
CACACTGGACACCAA-NFQ-MGB3′) specific for the
satellite region of the nuclear DNA of T. cruzi; 0,5X Taq-
Man RNAseP Control Reagents kit (VIC/TAMRA) from
Applied Biosystems, in a final volume of 20 μL [15]. Cycling
conditions were a first step at 95°C for 5 min, followed by
40 cycles at 94°C for 15 sec and 58°C for 1 min. The ampli-
fications were carried out in an ABI Prism 7500 Fast device
Figure 1 DNA detection in serum, blood and T. cruzi samples
by Real Time qPCR. Whole blood was spiked with Exo-IPC (1X) or T.
cruzi cells (1 par. eq./ mL) before serum preparation. Results are expressed
as the media of Threshold cycles (Ct) and represent the average from five
replicate samples ± Standard deviation. *, ** p < 0.05.
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blood and serum were constructed by serial dilution of
DNA extracted from blood samples spiked with T. cruzi
epimastigotes (CL-Brener), ranging from 105 to 0.5 parasite
equivalents per milliliter of blood (par. eq./mL). For serum
samples, whole blood was spiked with T. cruzi prior to
serum preparation and DNA extraction.
Evaluation of DNA migration to serum after blood
coagulation
In order to verify DNA migration to serum after blood
coagulation, the TaqMan® Exogenous Internal Positive
Control Reagents (Exo-IPC DNA) from Applied Biosys-
tems were used. This kit contains a synthetic DNA,
without homology with any DNA sequence available on
public databanks, together with a set of specific primers
and TaqMan probe (VIC/TAMRA). Five milliliters of
whole blood samples were spiked with Exo-IPC DNA or
T. cruzi CL-Brener epimastigotes to reach a final con-
centration of [1X] or 10 parasites/mL respectively, prior
to blood coagulation and serum isolation. DNA extrac-
tion and qPCR assays were conducted as described
above.
Statistical analysis
Experiments were performed in five replicates. Data
were expressed as arithmetic means or average ± stand-
ard deviation. Student’s t-test or Mann–Whitney Rank
Sum test were used to analyze the statistical significance
of the observed differences. A p-value of less than 0.05
was considered statistically significant. All the analyses
were performed with Sigmaplot for Windows Version
12.0 (Systat Software, Inc.).
Results
In this study the potential of serum samples to be used
for the detection and quantification of T. cruzi load by
real time qPCR was evaluated. At first, to evaluate the
DNA migration to serum after blood coagulation, serum,
blood and T. cruzi cultivated samples were compared by
analyzing the resultant Ct values in multiplex qPCR as-
says, where the human RNase P was used as an internal
amplification control [15,20] , and Exo-IPC was used as
an exogenous positive control (Figure 1). For this experi-
ment T. cruzi epimastigotes (CL Brener) were used to
contaminate a seronegative blood sample in order to
reach final concentration of 10 parasites/mL in whole
blood, before serum preparation. Following blood coagu-
lation and serum obtaining, it was observed that T.
cruzi, Exo-IPC and RNAse P targets were detected in
DNA extracted from serum samples (Cts means were
32.48, 29.38 and 30.15, respectively), showing the migra-
tion of parasite, exogenous and human DNAs to serum
during blood coagulation. Nevertheless, these Ct valueswere higher in serum than in blood or cultivated T. cruzi
samples (p < 0.05; Ct means for blood samples: 25.22 [T.
cruzi]; 27.90 [Exo-IPC] and 26.31 [RNAseP] and Ct
means for T. cruzi cultivated samples: 25.79 [T. cruzi]
and 27.02 [Exo-IPC]. Even with an increase in Ct values,
these results indicated the possibility of parasite detec-
tion in serum samples by qPCR.
Aiming to compare the reportable range of T. cruzi
DNA amplification between blood and serum samples,
three independent standard curves were constructed
ranging from 105 to 0.5 par. eq./mL with DNAs ex-
tracted from spiked blood; serum derived from artifi-
cially contaminated blood; and T. cruzi DNA from
cultured CL Brener epimastigotes (Figure 2). Through
linear regression analysis, an increased linearity was
observed (R2 = 0.99) and adequate slopes (−3.51, −3.68
and −3.46 for serum, blood and T. cruzi cultivated
samples, respectively) for parasite quantification. The
standard curve from serum samples showed higher Ct
values than the ones yielded for blood and cultivated
T. cruzi samples, thus revealing lower parasite DNA
concentration in serum. Nevertheless, linearity and
curve slopes were equal or higher respectively, than
those observed for blood standard curve, indicating
the potential of serum samples to be used in the quan-
tification of T. cruzi DNA by Real Time qPCR.
In order to compare the sensitivity and specificity of
the duplex Real Time qPCR between serum and blood,
assays were carried out with a panel of clinical samples
from 40 chronic Chagas disease patients and 20 sero-
negative control patients. Twenty two individuals from
the Chagas disease group were female (mean age
57.77 years) and 18 individuals were male (mean age
51.61 years). To calculate the sensitivity and specificity
Figure 2 Reportable range for T. cruzi detection and
quantification by Real Time qPCR. TaqMan qPCR was carried out
with serial diluted DNA extracted from serum, blood or parasite
cultivated samples, ranging from 105 to 0.5 par. eq./mL, tested in
five replicates each. The equations obtained by linear regression are
indicated in the chart.
Figure 3 Comparison between parasite loads in serum and
blood samples from chronic Chagas disease patients. Gray
circles and black squares represent T. cruzi quantification in serum
and blood respectively, by duplex Real Time qPCR assays. Median
values are indicated by horizontal lines.
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each individual, two serological tests using distinct anti-
gens preparation were performed (conventional and re-
combinant ELISA), and the results were concordant
between them. The qPCR showed sensitivities of 97.5
and 95% for T. cruzi DNA detection in blood and serum
samples, respectively, and 100% specificity for both sam-
ples (Table 1).
To estimate parasite load through the multiplex Real
Time PCR for absolute quantification, the correspondent
standard curves were used for blood and serum samples,
as described in Material and Methods section. For blood
samples, parasite load varied from 0.067 to 2.553 with a
median of 1.23 par. eq./mL. In comparison, for serum
samples, the quantification varied from 0.085 to 2.03
with a median of 1.12 par. eq./mL (Figure 3). No signifi-
cant difference was observed between the median values
for these samples. As a matter of fact, the estimated
parasite loads for these chronic patients were very low
and near the inferior limit of the qPCR dynamic range,
which can interfere in the precision of T. cruzi
quantification.Table 1 Sensitivity and specificity of the real time qPCR
in blood and serum samples
Blood samples Serum samples
ELISA + ELISA - ELISA + ELISA -
qPCR + 39 (97.5%) 0 (0%) 38 (95%) 0 (0%)
qPCR - 1 (2.5%) 20 (100%) 2 (5%) 20 (100%)
Total 40 20 40 20
To calculate Sensitivity and Specificity values, serology was considered as
gold standard.Patients were divided into 4 groups, according to the
clinical manifestation of Chagas disease: Cardiac Form
(CF = 23), Digestive Form (DF = 4), Indeterminate Form
(IF = 6) and Mixed Form (MF = 7). When patients were
analyzed according to their clinical manifestations, no
significant difference was observed in the parasite load
medians between the distinct forms of the disease, even
in blood (MF = 1.11, CF = 1.39, DF = 0.68, IF = 1.18 par.
eq./mL) or serum (MF = 0.85, CF = 1.17, DF = 0.85, IF =
0.86 par. eq./mL) (Figure 4). Nevertheless, some patients
presenting mixed (cardiodigestive) and cardiac forms
showed a slight increase in parasitemia in both types of
samples. However, as observed in Figure 3, all parasite
loads were very low and can compromise the quantifica-
tion precision.
Although the number of patients evaluated in this
study is quite small, our data raised a discussion regard-
ing the application of Real Time qPCR in serum samples
for the diagnosis and quantification of T. cruzi, in order
to follow-up Chagas disease patients, especially in situa-
tions where serum is the only available sample.
Discussion
Currently, WHO recommends the use of 2 simultaneous
serological tests for the diagnosis of chronic Chagas dis-
ease, as indirect haemagglutination, indirect immuno-
fluorescence and enzyme-linked immunosorbent assays,
based on detection of parasite-specific antibodies [9].
However, there is an elevated number of inconclusive re-
sults in blood banks worldwide, resulting in blood bag
losses and increasing the risk of transmission by blood
transfusion [5,6,8]. The Brazilian guideline for chronic
Chagas disease diagnosis determines the use of PCR to
confirm inconclusive serological tests, resulting in a new
Figure 4 Distribution of parasite loads in blood and serum between chronic patients with distinct clinical manifestations of Chagas
disease. A. Black symbols represent parasite loads quantified in blood samples by multiplex Real Time qPCR. B. Gray symbols represent the
respective parasite loads in serum samples. Median values are indicated by a straight horizontal line. MF = Mixed Form (n = 7); CF = Cardiac Form
(n = 23); DF = Digestive Form (n = 4); IF = Indeterminate Form (n = 6).
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investigate the feasibility of Chagas disease molecular
diagnosis and parasite load quantification using the same
serum sample yielded for serological tests, based on pre-
vious studies that confirmed the use of serum samples
for T. cruzi DNA detection by PCR [21]. Nevertheless,
from our knowledge, this is the first report for using a
multiplex Real Time qPCR assay able to detect and
quantify T. cruzi from serum samples.
In this study, it is evident that the migration of T. cruzi
DNA to serum occurs after blood coagulation. When we
spiked whole blood with an exogenous DNA or living T.
cruzi epimastigotes prior to serum isolation, both DNAs
could be detected by multiplex Real Time PCR assay, in
conjunction with human DNA from nucleated blood
cells. As expected, the higher Ct values observed in
serum, in comparison with blood and parasite cultivated
samples, indicated that only part of parasite and human
DNA migrates to serum after blood coagulation. Never-
theless, the sensitivity for T. cruzi detection in chronic
Chagas disease patients was only slightly lower in serum
(95.0%) than blood (97.5%), and the same specificity
(100%) was observed for both samples (Table 1), which
makes it possible to use serum samples to detect T. cruzi
DNA by Real Time qPCR. Using serological methods as
gold standard, clinical sensitivity for conventional and
Real Time PCR assays presents great variability among
distinct studies [17,22-26]. In addition, using cruzi1/
cruzi2 primers and cruzi 3 TaqMan probe, Duffy et al.
[17] reported sensitivity values ranging from 60.3 –
100% for T. cruzi detection in blood samples from pa-
tients from different geographical areas (Venezuela,
Cochabamba, Argentina and North Argentina), infected
by distinct transmission routes (oral infection, chronic
Chagas disease and newborns from chronic Chagas dis-
ease mothers), and presenting different parasite load me-
dians (2.75 – 691.8 parasite equivalents/ mL). On the
other hand, Fitzwater et al. [26] reached 60.1%, 46.5%and 40% sensitivity from clot, buffy coat and whole
blood samples, respectively, in a conventional PCR assay
using 121/122 primers. Indeed, multiple factors seem to
influence these results, as the primers used (kDNA vs
Sat-DNA), DNA extraction method, PCR reagents, T.
cruzi genotype (DTUs) and parasite load. Following our
methodology, even considering low parasite loads, we
reached high and similar sensitivity values for blood and
serum.
Nowadays, efforts are being done to standardize Real
Time qPCR for T. cruzi quantification in blood samples.
Following the recommendations from the international
workshop promoted by PAHO/WHO in 2011, Duffy
et al. [17] reported the analytical performance of a
Multiplex Real-Time qPCR for the quantification of T.
cruzi satellite DNA in blood samples. They observed a
reportable range between 1 and 6 log10 par. eq./10 mL
for a TcI isolate (Silvio X10) and 0.25 to 6 log10 par. eq./
10 mL for a TcVI isolate (CL Brener). In addition, for
the CL Brener isolate, it was observed a Limit of Detec-
tion (LOD) and Limit of Quantification (LOQ) of 0.6979
and 1.531 par. eq./mL, respectively. Herein, using the
same set of primers for T. cruzi nuclear satellite DNA
multiplexed with human RNAse P gene instead of using
the Internal Amplification Control (IAC), we observed a
reportable range from 105 to 0.5 par. eq./mL (Figure 2)
for DNAs extracted from serum, blood or T. cruzi culti-
vated samples (CL Brener). Likewise, our results were
feasible for parasite load quantification in Chagas disease
patients with moderated parasitemia.
In this study, the low parasite load achieved in blood
or serum samples reproduced the findings observed in
recent studies regarding the use of qPCR for chronic
Chagas disease patients [16,17,20]. The parasite load
median in blood (1.23 par. eq./mL) was not statistically
different from the one achieved from serum samples
(1.12 par. eq./mL) (Figure 3), which corroborates the
use of DNA extracted from serum for qPCR assays.
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termined [17], several patients herein analyzed, pre-
sented parasite load below the LOQ, which means these
samples were detectable but not quantifiable. When pa-
tients presenting distinct clinical manifestations were
compared (Figure 4), we also could not observe significant
differences between the parasite load medians from the
groups evaluated, although many patients presenting the
cardiac form (CF) seems to have higher parasite load in
blood and serum samples. Unfortunately, in this study,
there was a limitation concerning the number of analyzed
patients, particularly for those with the digestive form of
the disease. In the future, a robust investigation joining a
representative group of patients with all Chagas disease
clinical manifestations will be necessary to properly inves-
tigate parasite load as a biomarker for progression and se-
verity of Chagas disease. The advances achieved here
suggest the use of serum samples, currently maintained in
serum banks, for retrospective studies regarding the dis-
ease development and to the follow-up of patients under
treatment. Meanwhile, a new study with considerable
higher numbers of Chagas disease patients, especially
those asymptomatic individuals who can act as potential
blood donors, must be performed to validate this molecu-
lar diagnostic assay in blood banks worldwide.
Conclusions
Taken together our data suggest the potential of serum
samples to be used for molecular diagnosis and parasite
load quantification by quantitative Real Time PCR assays.
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